Redeye comments on yesterday’s Key Opinion Leader (KOL) event, which focused heavily on the biology of the tumour microenvironment in pancreatic ductal adenocarcinoma (PDAC) and highlighted how Cantargia’s lead asset, nadunolimab (CAN04), can be combined with upcoming RAS inhibitors.
LÄS MER
